This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Drug Development

Interview: C4 Therapeutics targets protein degradation

Posted by on 11 July 2017
Share this article

Finding a way to trick the ubiquitin proteasome system, C4 Therapeutics, a spin-out from Harvard's Dana-Farber Cancer Institute, has developed a way to target any disease-causing protein for degradation. Fresh from announcing the creation of the company, a USD 73 million series A financing, and a deal with Roche which has a potential biodollar value north of USD 750 million, C4 Therapeutics co-founder and executive chairman Marc Cohen explains to Informa Pharma Insights global director of content Mike Ward how the approach works.

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down